Rick has been CEO at Nocion since August 2018. He has over two decades of experience in drug development across an array of platforms and disease states, and has been with several start-ups from founding through acquisition. Most recently, he was the Chief Scientific Officer and a founder of Civitas Therapeutics. Civitas was acquired by Acorda, whereupon he became their Chief Technology Officer and Civitas’ lead asset—a novel dry powder inhalation therapy to treat motor issues in Parkinson’s patients—has been approved by the FDA as InbrijaTM.
 Rick was previously the Chief Scientific Officer and Sr. Vice President of Research and Development at Pulmatrix. He was previously the Vice President of Research and Development at Alkermes, overseeing many facets of product development across pulmonary, injectable and oral platforms. Rick was an original member of Advanced Inhalation Research (AIR®), where he oversaw product development.

Rick held several academic posts prior to joining AIR. He received his B.Sc. in Chemical Engineering from the University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

• 

  President in Nocion Therapeutics

  Charging forward

• 

  Chief Executive Officer (CEO) in Nocion Therapeutics

  Charging forward